公告显示，此次合作涉及科伦博泰一款靶向整合素β6(ITGB6)并以拓扑异构酶抑制剂为载荷的抗体偶联 药物(ADC) SKB105，以及Crescent一款程序性细胞死亡-1(PD-1)×血管内皮生长因子(VEGF)双特异性抗 体CR-001。这两款候选药物均正在开发用于治疗实体瘤，预计于2026年第一季度开展1/2期单药治疗临 床试验。 基于此次合作，科伦博泰将向Crescent收取8000万美元的首付款，并有资格收取高达12.5亿美元的里程 碑付款，以及基于SKB105净销售额的中个位数至低双位数百分比的分级特许权使用费。Crescent将向科 伦博泰收取2000万美元的首付款，并有资格收取高达3000万美元的里程碑付款，以及基于CR-001净销 售额的低至中个位数百分比的分级特许权使用费。 北京商报讯（记者 丁宁）12月4日晚间，科伦药业（002422）发布公告称，公司近日获悉，公司控股子 公司四川科伦博泰生物医药股份有限公司（以下简称"科伦博泰"）与Crescent Biopharma, Inc.及其全资 子公司Crescent Biopharma Operating Company, LLC(以下合称 ...

Core Viewpoint - The strategic partnership between Sichuan Kelun Biotech Co., Ltd. and Crescent Biopharma aims to develop and commercialize innovative cancer therapies, including new combination treatments [1][2]. Group 1: Partnership Details - The collaboration involves Kelun Biotech's SKB105, an antibody-drug conjugate targeting integrin β6, and Crescent's dual-specific antibody CR-001, which targets PD-1 and VEGF, both intended for solid tumor treatment [2]. - The partnership grants Crescent exclusive rights to research, develop, manufacture, and commercialize SKB105 outside of Greater China, while Kelun Biotech receives exclusive rights for CR-001 within Greater China [2]. Group 2: Financial Aspects - Kelun Biotech will receive an upfront payment of $80 million from Crescent, with potential milestone payments up to $1.25 billion and tiered royalties based on SKB105's net sales [3]. - Crescent will pay Kelun Biotech an upfront fee of $20 million, with milestone payments up to $30 million and tiered royalties based on CR-001's net sales [3]. Group 3: Strategic Implications - This collaboration enhances Kelun Biotech's differentiated oncology pipeline and accelerates the global development of SKB105, increasing its commercial potential and expanding the company's global partnership network [3]. - The partnership leverages both companies' resources to explore new monotherapy and combination therapy strategies in cancer treatment, maximizing the therapeutic potential of both candidates in China and globally [3].

Core Insights - The company, Kelun Pharmaceutical, has established a strategic partnership with Crescent Biopharma to jointly develop and commercialize oncology treatment methods [1] Group 1: Partnership Details - The collaboration involves two candidate drugs: Kelun's SKB105 and Crescent's CR-001 [1] - Kelun grants Crescent exclusive rights to develop SKB105 in markets outside the US, Europe, and Greater China, while Crescent grants Kelun exclusive rights to develop CR-001 in Greater China [1] Group 2: Financial Aspects - Kelun will receive an upfront payment of $80 million from Crescent and has the potential to earn up to $1.25 billion in milestone payments [1] Group 3: Strategic Implications - This partnership allows Kelun to enhance and diversify its oncology research pipeline by incorporating CR-001 [1]

Core Insights - The company announced a strategic partnership with Crescent Biopharma to jointly develop and commercialize oncology treatments [1] - The collaboration involves two candidate drugs: SKB105 from the company and CR-001 from Crescent [1] - The company grants Crescent exclusive rights to develop SKB105 outside the US, Europe, and Greater China, while Crescent grants the company exclusive rights to develop CR-001 in Greater China [1] Financial Aspects - The company will receive an upfront payment of $80 million from Crescent [1] - There is potential for the company to earn up to $1.25 billion in milestone payments [1] Research and Development - The partnership includes the development of both monotherapy and combination therapy for the two candidate drugs [1] - The collaboration enhances the company's differentiated oncology research pipeline by incorporating CR-001 [1]

此次合作涉及科伦博泰一款靶向整合素β6(ITGB6)并以拓扑异构酶抑制剂为载荷的抗体偶联药物 (ADC)SKB105，以及Crescent一款程序性细胞死亡-1(PD-1)×血管内皮生长因子(VEGF)双特异性抗体CR- 001。这两款候选药物均正在开发用于治疗实体瘤，预计于2026年第一季度开展1/2期单药治疗临床试 验。 人民财讯12月4日电，科伦药业（002422）12月4日公告，公司控股子公司科伦博泰与Crescent Biopharma,Inc.及其全资子公司(合称"Crescent"或"Crescent Biopharma")已建立战略合作伙伴关系，共同 开发和商业化肿瘤治疗手段(包括新型联用疗法)。 ...

Core Viewpoint - The company has established a strategic partnership with Crescent Biopharma to jointly develop and commercialize cancer treatment methods, which includes significant financial arrangements and potential future earnings from sales royalties [1] Financial Arrangements - Sichuan Kelun Botai Biopharmaceutical Co., Ltd. will receive an upfront payment of $80 million from Crescent Biopharma [1] - The company is eligible for up to $1.25 billion in milestone payments based on the partnership's success [1] - Additionally, Kelun Botai will receive tiered royalties ranging from mid-single to low-double digits percentage based on the net sales of SKB105 [1] Additional Financial Terms - Crescent Biopharma will pay an upfront fee of $20 million to Kelun Botai and is eligible for up to $30 million in milestone payments [1] - Crescent will also pay tiered royalties based on the net sales of CR-001, starting from low to mid-single digits percentage [1] Control Change Provisions - If there is a change in control at Crescent or if they enter into sublicensing agreements with third parties, Kelun Botai may receive additional payments [1]

一、合作基本情况 此次合作涉及科伦博泰一款靶向整合素β6(ITGB6)并以拓扑异构酶抑制剂为 载荷的抗体偶联药物(ADC) SKB105，以及 Crescent 一款程序性细胞死亡-1(PD-1) ×血管内皮生长因子(VEGF)双特异性抗体(以下简称"双抗") CR-001。这两款 候选药物均正在开发用于治疗实体瘤，预计于 2026 年第一季度开展 1/2 期单药 治疗临床试验。 根据合作条款，科伦博泰授予 Crescent 在美国、欧洲及所有其他大中华地区 （包括中国大陆、香港、澳门及台湾）以外市场研究、开发、生产和商业化 SKB105 的独家权利。Crescent 则授予科伦博泰在大中华地区研究、开发、生产和商业化 CR-001 的独家权利。此次合作包括开发两款候选药物的单药疗法，以及评估 CR-001 与 SKB105 的联用疗法。科伦博泰及 Crescent 均有权独立开发 CR-001 的其他联用方案，包括 CR-001 与各自专有的 ADC 管线资产联用。 基于此次合作，科伦博泰将向 Crescent 收取 8,000 万美元的首付款，并有资 格收取高达 12.5 亿美元的里程碑付款，以及基于 S ...

Core Viewpoint - Kolon Pharmaceutical's subsidiary, Kolon Biotech, has established a strategic partnership with Crescent Biopharma to jointly develop and commercialize cancer treatment methods, focusing on two drugs for solid tumors [1] Group 1: Partnership Details - The collaboration involves Kolon Biotech's SKB105 and Crescent's CR-001, both aimed at treating solid tumors [1] - Kolon Biotech grants Crescent exclusive rights in markets outside Greater China, while Crescent grants Kolon Biotech exclusive rights in Greater China [1] Group 2: Financial Terms - Kolon Biotech will receive an upfront payment of $80 million, along with up to $1.25 billion in milestone payments and royalties based on sales [1] - Crescent will receive an upfront payment of $20 million, with potential milestone payments of up to $30 million and royalties based on sales [1]

Core Viewpoint - Sichuan Kelun-Biotech and Crescent Biopharma have formed a strategic partnership to develop and commercialize oncology therapeutics, specifically focusing on CR-001 and SKB105, with plans to enter Phase 1/2 clinical trials in Q1 2026 [1][2][4] Group 1: Partnership Details - The collaboration grants Kelun-Biotech exclusive rights to develop and commercialize CR-001 in Greater China, while Crescent holds exclusive rights for SKB105 in the US, Europe, and other markets outside Greater China [3] - The partnership aims to explore both monotherapy and combination strategies for CR-001 and SKB105, with both companies retaining rights to independently develop CR-001 in additional combinations [3] Group 2: Financial Aspects - Kelun-Biotech will receive an upfront payment of US$80 million from Crescent, with potential additional milestones of up to US$1.25 billion and tiered royalties on net sales of SKB105 [4] - Crescent will receive an upfront payment of US$20 million from Kelun-Biotech, along with potential milestones of up to US$30 million and tiered royalties on net sales of CR-001 [4] Group 3: Product Information - CR-001 is a PD-1 x VEGF bispecific antibody designed for solid tumors, showing promising preclinical results in anti-tumor activity and potential for combination therapies [6] - SKB105 is an integrin beta-6-directed ADC with a topoisomerase payload, targeting solid tumors while minimizing systemic toxicity, and is also set to enter Phase 1/2 trials in Q1 2026 [7] Group 4: Company Backgrounds - Kelun-Biotech focuses on R&D, manufacturing, and commercialization of innovative drugs, with over 30 ongoing projects and a commitment to addressing unmet medical needs globally [8] - Crescent Biopharma aims to build a leading oncology company with a diverse pipeline, including CR-001 and novel ADCs, to advance transformative therapies for cancer patients [9]

Financial Engineering Research - The Q4 style rotation model indicates signals for small-cap and growth stocks, with recommended sectors including power equipment and renewable energy [2][4] - The dual-driven rotation strategy for Q4 yields a composite score of -1, predicting a preference for small-cap stocks [4] - The value-growth rotation strategy for Q4 shows a composite score of -3, indicating a preference for growth stocks [4] Biopharmaceutical Research - Continuous recommendation for innovative drugs and medical devices along the industry chain [5][6] - Maintain "overweight" ratings for A-share stocks such as Heng Rui Medicine, Ke Lun Pharmaceutical, and others, included in the December monthly portfolio [6][7] - The biopharmaceutical sector underperformed the broader market in November, with a decline of 3.6% compared to a 1.7% drop in the Shanghai Composite Index [7][8] Industry Rotation Insights - In November, the composite factor strategy yielded an excess return of -0.58%, while the single-factor strategy showed an excess return of -0.83% [4] - For December, recommended sectors for the single-factor strategy include banking, construction, non-bank financials, and power equipment [4] - The composite factor strategy recommends sectors such as telecommunications, comprehensive finance, and public utilities [4] Consumer Electronics - The launch of the AI phone assistant by Doubao signifies the upcoming era of AI smartphones, enhancing the hardware ecosystem [20][21] - Doubao's AI assistant can execute complex commands and integrate deeply with operating systems, providing a seamless user experience [21][22] - The assistant's capabilities include cross-application tasks, enhancing user interaction with various platforms [21][22] Medical Commercial Sector - The report maintains an "overweight" rating for leading chain pharmacies, anticipating recovery driven by supply-side clearing and demand-side recovery [15][16] - The retail scale of China's physical pharmacies is projected to reach 611.9 billion yuan in 2024, despite a decline of 1.8% year-on-year [16][17] - The report highlights a recovery trend in drug sales, particularly in essential medicines, amidst a challenging consumer environment [17][18] New Materials Sector - The company achieved a revenue growth of 2.31% year-on-year in the first three quarters of 2025, driven by new materials [27][28] - The company is actively expanding its new materials business, with significant projects underway [28] - The controlling shareholder plans to increase its stake in the company, reflecting confidence in future growth prospects [27][28]